帕博利珠单抗治疗冒烟型骨髓瘤的初步研究:临床、免疫与基因组分析
1例(8%)获严格完全缓解且持续27个月,11例(85%)疾病稳定,1例(8%)进展。3例因免疫相关不良事件停药。免疫与转录组分析提示应答者存在预存免疫应答,非应答者T细胞耗竭增加。
要点
- 帕博利珠单抗在中高危冒烟型骨髓瘤中显示部分免疫应答,1例获持续严格完全缓解。
- 免疫相关不良事件导致3例停药,包括转氨酶升高和肾小管间质性肾炎。
- 基线骨髓免疫特征和干扰素-γ信号可能预测应答。
核心结论
- 冒烟型骨髓瘤在部分患者中具有免疫原性,增强抗肿瘤T细胞应答的治疗可能有效预防进展。
主要发现
- 1例(8%)获严格完全缓解,骨髓二代测序10-4阴性持续27个月。
- 11例(85%)疾病稳定,1例(8%)进展。
- 3例因免疫相关不良事件停药:2例转氨酶升高,1例肾小管间质性肾炎。
- 基线骨髓免疫分析显示应答者存在预存免疫应答标志,非应答者T细胞耗竭增加。
- 基线骨髓转录组测序显示应答者干扰素-γ信号增强。
临床怎么用
- 帕博利珠单抗可能作为中高危冒烟型骨髓瘤的早期干预选择,但需警惕免疫相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma is, in most patients, an incurable cancer. Its precursors can be identified with routine tests setting the stage for early intervention to prevent active myeloma. We investigated the efficacy and safety of pembrolizumab, an antiprogrammed cell death 1 antibody, in smoldering myeloma patients with intermediate/high risk of progression to symptomatic myeloma. Thirteen patients were treated with a median number of 8 cycles. One patient achieved a stringent complete response with bone marrow next-generation sequencing negativity at 10-4 that is ongoing at 27 months (8%); 11 had stable disease (85%), and 1 progressed (8%). Three patients discontinued therapy due to immune-related adverse events: 2 with transaminitis and 1 due to tubulointerstitial nephritis. Immune profiling of bone marrow samples at baseline showed markers associated with a preexisting immune response in the responder compared with nonresponders and features of increased T-cell exhaustion in nonresponders. Consistent with this, transcriptome sequencing of bone marrow samples at baseline revealed an increased interferon-γ signature in the responder compared with the nonresponders. In summary, our results suggest that smoldering myeloma may be immunogenic in a subset of patients, and therapies that enhance antitumor T-cell responses may be effective in preventing its progression. This trial was registered at www.clinicaltrials.gov as #NCT02603887.
引用
- Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019. PMID: 31405950. doi:10.1182/bloodadvances.2019000300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。